ALTO NEUROSCIENCE, INC.

ALTO NEUROSCIENCE, INC. logo
🇺🇸United States
Ownership
Public
Established
2019-01-01
Employees
63
Market Cap
$318.9M
Website
http://www.altoneuroscience.com
Clinical Trials
Related News

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Phase 4
Withdrawn
Conditions
Major Depressive Disorder
Interventions
Drug: Duloxetine
Drug: Bupropion
First Posted Date
2020-05-14
Last Posted Date
2020-10-19
Lead Sponsor
Alto Neuroscience
Registration Number
NCT04388189
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy